Addiction Research

According to the World Health Organization (WHO), addiction is 'a chronic disease of the central nervous system that is characterized by a loss of control over impulsive behavior that leads to compulsive drug seeking and taking, and to relapses even after months of abstinence'. Addiction is a complex neuroadaptive process, where drugs of abuse alter cellular and molecular aspects of neural function. The brain circuits mediating the various behavioral effects of these drugs are rendered more, or less, responsive to those effects.

Addiction Research Products Targets

Products for Addiction Research - Page 16

Cat.No. Product Name Information/Activity
BCC7954 (±)-SLV 319 (±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC50 of 22 nM.
BCC1898 Rimonabant hydrochloride Rimonabant hHydrochloride (SR 141716A Hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an Ki of 1.8 nM. Rimonabant hHydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).
BCC6144 TC-C 14G 656804-72-7
BCC4411 Org 27569 Org 27569 is a potent CB1 receptor allosteric modulator, which increases agonist binding, yet blocks agonist-induced CB1 signaling.
BCC7401 Tocrifluor T1117 1186195-59-4
BCC5971 HU 308 Potent and selective CB<sub>2</sub> agonist
BCC5744 JWH 015 155471-08-2
BCC1353 AM630 6-Iodopravadoline (AM630) is a selective CB2 antagonist with Ki of 31.2 nM, and displays 165-fold selectivity over CB1 receptors.
BCC6282 COR 170 1048039-15-1
BCC7380 JTE 907 282089-49-0